Compare Diageo plc (DEO) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Smith & Nephew plc — how do they compare? Diageo plc trades at $86.83 (market cap $47.67B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Diageo plc is far larger — about 4.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Smith & Nephew plc for 121 Days on average.
| DEO | SNN | |
|---|---|---|
Market Cap | $47.67B | $11.10B |
Volume | 893,372 | 1,051,703 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $37.17 |
52-Week Low | $72.47 | $26.42 |
Typical Hold Time | 66 Days | 121 Days |
Enterprise Value | $68.09B | $14.13B |
Dividend Yield | 2.3% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical indicators and strong analyst support. The company demonstrates solid fundamentals with consistent earnings beats, a 15.82% ROE, and positive cash flow generation. Recent corporate developments include a new CFO appointment and marketing initiatives across key brands, though revenue declined to $19.6B in 2026 with margin compression.
The stock presents a compelling turnaround opportunity with analyst consensus favoring bullish sentiment (48.65% buy ratings). Key catalysts include cost-saving initiatives and brand revitalization, while risks involve US market challenges, regulatory scrutiny in India, and ongoing margin pressure. The current valuation at 27.91 P/E appears reasonable given the growth potential.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
